Fig. 5From: IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patientsThe comparison of anti-SARS-CoV-2 IgG APR and Ab levels in lymphoma patients treated with and without ASCT therapy (A and B). The comparison of anti-SARS-CoV-2 IgG APR and Ab levels in BCL and non-BCL subtypes treated with and without ASCT (C and D)Back to article page